Director/PDMR Shareholding

RNS Number : 5086U

ReNeuron Group plc

28 March 2023

 

ReNeuron Group plc

("ReNeuron" or the "Company")

Share Purchase by Executive Chairman

ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , announces that Iain Ross, Executive Chairman of the Company, has today purchased 100,000 of the Company's ordinary shares of 1p each ("Ordinary Shares").

Name	Title	Number of Ordinary Shares purchased	Resulting beneficial interest in the Company's Ordinary Shares	Percentage of Company's Total Voting Rights
Iain Ross	Executive Chairman	100,000	400,000	0.70%

  ENDS

Enquiries:

ReNeuron		www.reneuron.com/investors
Iain Ross, Executive Chairman		Via Walbrook PR
John Hawkins, Chief Financial Officer
Allenby Capital Limited (Nominated Adviser and Broker)		[phone]
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)		[phone] or [e-mail]
Paul McManus / Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects.  ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit  www.reneuron.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Iain Ross
2	Reason for the notification
a)	Position/status	Executive Chairman and Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00BF5G6K95
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Price(s) and volume(s)	Price(s)  Volume(s) 9.245p 100,000
d)	Aggregated information	100,000 ordinary shares at an average price of 9.245p at a total value of £9,245.00
e)	Date of the transaction	28 March 2023
f)	Place of the transaction	London Stock Exchange AIM Market

 

END

 

 

DSHFLFLVVTITFIV